康臣葯業集團有限公司 01681Stock Information

Stock Information · Old Rules
// Company Overview //
Stock Name康臣葯業集團有限公司
Stock Code01681
Company Full Name康臣葯業集團有限公司
Industry醫療保健
Principal Activities主要在中國從事生產及銷售中成藥及醫用成像對比劑。
Listing Date2013-12-19
Listing Rules EraOld Rules
Listing Rules ChapterNo data
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國廣東省廣州市黃埔區經濟技術開發區東區東鵬大道71號
Business Address (Hong Kong)No data
Place of IncorporationNo data
Listing MethodNo data
Listing BoardMain Board
Websitehttp://www.chinaconsun.com
Share Registrar香港中央證券登記有限公司
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo data
// Offering Information //
Prospectus Date2013-12-09
Offer PriceHK$ 4.36 / shares
Total Funds RaisedHK$ 545,000,000
// Valuation & Financials //
Market Cap (at Offer Price)HK$ 0
// First Day Performance
First Day CloseLoading...
First Day OpenHK$ 5.0
First Day Change12.29%
First Day Volume189773000.0
First Day Turnover931137000.0
// Price Chart //
Loading...
// Use of Proceeds
Use of Proceeds1、約393.5百萬港元(約所得款項凈額總額約40%)將用于我們的基礎設施投資:(i)興建位于廣東省廣州市的新生產基地、倉庫及配套設施,以及購買及安裝該處的生產線;(ii)購買及安裝位于內蒙古自治區通遼市生產基地的新生產設施,(iii)為位于內蒙古自治區通遼市的檢驗中心購買質量控制設備;(iv)為本集團用于生產其他藥品的現有生產線升級;及(v)為本集團的信息系統升級; 2、約196.8百萬港元(約所得款項凈額總額約20%)將用于研發活動,以開發新產品; 3、約147.6百萬港元(約所得款項凈額總額約15%)將用于擴大我們的現有市場推廣及分銷網絡,以增加我們的市場滲透水平至覆蓋更多終端客戶,如縣級醫療機構和小區及農村保健中心,并相應增加我們的市場份額; 4、約147.6百萬港元(約所得款項凈額總額約15%)將用于并購擁有腎病中藥種植能力及該等專注于腎病口服現代中成藥或醫用成像對比劑的企業。我們目前并無任何具體的并購計劃或目標,亦未有與任何潛在目標訂立任何正式協議; 5、約98.4百萬港元(約所得款項凈額總額約10%)將用于營運資金及其他一般企業用途。
// Underwriting Syndicate //
独家保荐人 (1)
中银国际亚洲有限公司
整体协调人 (1)
中银国际亚洲有限公司
联席账簿管理人 (1)
中银国际亚洲有限公司
联席牵头经办人 (1)
中银国际亚洲有限公司
// Cornerstone Investors //
#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 景林资产管理有限公司 246,885,000 HKD 5.70% 6 months 2014-06-19
// Directors & Management //
Chairman安猛
Company Secretary高海恩
No director data available.
// Major Shareholders //
Major Shareholders & Holdings安郁寶(25.74%);黎倩(16.87%);楊惠波(13.64%)
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics